Condition
Multiple Sclerosis, Progressive
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (2)
Trial Status
Completed3
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06841068Phase 1WithdrawnPrimary
Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis
NCT06683612Phase 1Completed
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
NCT02950454Not ApplicableCompletedPrimary
The Effect of High Intensity Interval Training on Cardiovascular Fitness in People With Progressive Multiple Sclerosis.
NCT02301247Not ApplicableCompletedPrimary
Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS)
Showing all 4 trials